Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Onconova Therapeutic (ONTX)

Onconova Therapeutic (ONTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,357
  • Shares Outstanding, K 179,654
  • Annual Sales, $ 2,180 K
  • Annual Income, $ -21,500 K
  • 60-Month Beta 2.07
  • Price/Sales 22.23
  • Price/Cash Flow N/A
  • Price/Book 2.91
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/10/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.75
  • Growth Rate Est. (year over year) +97.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1901 +56.23%
on 09/04/20
0.4396 -32.44%
on 09/21/20
-0.0459 (-13.39%)
since 08/24/20
3-Month
0.1901 +56.23%
on 09/04/20
1.5600 -80.96%
on 07/21/20
-0.2828 (-48.78%)
since 06/24/20
52-Week
0.1027 +189.19%
on 11/26/19
1.5600 -80.96%
on 07/21/20
-0.8630 (-74.40%)
since 09/24/19

Most Recent Stories

More News
Thinking about buying stock in Onconova Therapeutics, Norwegian Cruise Line, Ampio Pharmaceuticals, Delta Air Lines, or Plug Power?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONTX, NCLH, AMPE, DAL, and PLUG.

AMPE : 0.8400 (-0.63%)
DAL : 29.01 (-1.86%)
NCLH : 14.63 (-3.56%)
ONTX : 0.2970 (+9.96%)
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021

ONTX : 0.2970 (+9.96%)
Innovative Diagnostic Techniques are in Demand as Social Distancing Rules Ease

, /PRNewswire/ -- The pandemic has drastically changed the world's social and economic landscape, and it's unclear what the next steps are in combating the spread of the viral infection. Now, that social...

SBFM : 0.0183 (+6.40%)
TPTW : 0.0590 (+4.42%)
CYDY : 3.3565 (-2.14%)
ONTX : 0.2970 (+9.96%)
VYST : 0.0335 (-9.46%)
Onconova Therapeutics Announces Participation at Upcoming Virtual Events

Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company plans to participate in several...

ONTX : 0.2970 (+9.96%)
Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors

Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the election of James J. Marino, JD, MBA as...

CLDX : 12.09 (-1.14%)
ONTX : 0.2970 (+9.96%)
Onconova's Cancer Study Fails to Meet Endpoint, Shares Down

Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.

BPTH : 3.95 (-1.17%)
BLRX : 1.6400 (+0.61%)
PCRX : 57.05 (-3.21%)
ONTX : 0.2970 (+9.96%)
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial

IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS)

ONTX : 0.2970 (+9.96%)
Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results

-- INSPIRE Phase 3 trial survival events reached

ONTX : 0.2970 (+9.96%)
Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes...

ONTX : 0.2970 (+9.96%)
Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes...

ONTX : 0.2970 (+9.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade ONTX with:

Business Summary

Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV,...

See More

Key Turning Points

2nd Resistance Point 0.3323
1st Resistance Point 0.3147
Last Price 0.2970
1st Support Level 0.2647
2nd Support Level 0.2323

See More

52-Week High 1.5600
Fibonacci 61.8% 1.0033
Fibonacci 50% 0.8313
Fibonacci 38.2% 0.6594
Last Price 0.2970
52-Week Low 0.1027

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar